Online inquiry

IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2876MR)

This product GTTS-WQ2876MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CCR4 gene. The antibody can be applied in Tropical spastic paraparesis, Adult T cell leukemia/lymphoma (ATL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005508.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1233
UniProt ID P51679
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ2876MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11994MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MM-121
GTTS-WQ10214MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LFB-R593
GTTS-WQ3425MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AV-299
GTTS-WQ6115MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA COR-001
GTTS-WQ10454MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY2541546
GTTS-WQ13561MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PRX-302
GTTS-WQ7930MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GSK3196165
GTTS-WQ6995MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA F-627
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW